A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
Status:
Completed
Trial end date:
2019-01-15
Target enrollment:
Participant gender:
Summary
Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to
assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in
healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Reven Pharmaceuticals, Inc.
Collaborators:
ERT Healthcare Company ERT: Clinical Trial Technology Solutions ICON plc